 Glycine
"Glycine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.
| Descriptor ID |
D005998
|
| MeSH Number(s) |
D12.125.481
|
| Concept/Terms |
Glycine- Glycine
- Aminoacetic Acid
- Acid, Aminoacetic
|
Below are MeSH descriptors whose meaning is more general than "Glycine".
Below are MeSH descriptors whose meaning is more specific than "Glycine".
This graph shows the total number of publications written about "Glycine" by people in this website by year, and whether "Glycine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 2 | 2 | | 1993 | 1 | 2 | 3 | | 1994 | 0 | 3 | 3 | | 1995 | 2 | 2 | 4 | | 1996 | 3 | 1 | 4 | | 1997 | 1 | 2 | 3 | | 1998 | 1 | 1 | 2 | | 1999 | 1 | 2 | 3 | | 2000 | 2 | 1 | 3 | | 2001 | 2 | 3 | 5 | | 2002 | 5 | 3 | 8 | | 2003 | 1 | 0 | 1 | | 2004 | 3 | 2 | 5 | | 2005 | 3 | 0 | 3 | | 2006 | 1 | 1 | 2 | | 2007 | 2 | 2 | 4 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 2 | 3 | | 2011 | 1 | 2 | 3 | | 2012 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 5 | 2 | 7 | | 2015 | 2 | 1 | 3 | | 2016 | 1 | 1 | 2 | | 2017 | 1 | 7 | 8 | | 2018 | 3 | 0 | 3 | | 2019 | 3 | 2 | 5 | | 2020 | 1 | 3 | 4 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Glycine" by people in Profiles.
-
Eroglu EC, Kucukgoz Gulec U, Vardar MA, Paydas S. GC-MS based metabolite fingerprinting of serous ovarian carcinoma and benign ovarian tumor. Eur J Mass Spectrom (Chichester). 2022 Feb; 28(1-2):12-24.
-
Swanson MA, Miller K, Young SP, Tong S, Ghaloul-Gonzalez L, Neira-Fresneda J, Schlichting L, Peck C, Gabel L, Friederich MW, Van Hove JLK. Cerebrospinal fluid amino acids glycine, serine, and threonine in nonketotic hyperglycinemia. J Inherit Metab Dis. 2022 07; 45(4):734-747.
-
Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey JK, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803.
-
Wall KP, Hart H, Lee T, Page C, Hawkins TL, Hough LE. C-Terminal Tail Polyglycylation and Polyglutamylation Alter Microtubule Mechanical Properties. Biophys J. 2020 12 01; 119(11):2219-2230.
-
Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Watts JM, Pollyea DA, Fathi AT, Tallman MS, Kantarjian HM, Stone RM, Quek L, Konteatis Z, Dang L, Nicolay B, Nejad P, Liu G, Zhang V, Liu H, Goldwasser M, Liu W, Marks K, Bowden C, Biller SA, Attar EC, Wu B. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020 05 12; 4(9):1894-1905.
-
Tap WD, Villalobos VM, Cote GM, Burris H, Janku F, Mir O, Beeram M, Wagner AJ, Jiang L, Wu B, Choe S, Yen K, Gliser C, Fan B, Agresta S, Pandya SS, Trent JC. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. J Clin Oncol. 2020 05 20; 38(15):1693-1701.
-
Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 02 13; 135(7):463-471.
-
Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, George JT, Gerstein HC, Hobbs T, Holman RR, Lawson FC, Leiter LA, Pfeffer MA, Reusch J, Riesmeyer JS, Roe MT, Rosenberg Y, Temple R, Wiviott S, McMurray J, Granger C. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. Circulation. 2020 03 10; 141(10):843-862.
-
Lowery MA, Burris HA, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019 09; 4(9):711-720.
-
Samet JM. Expert Review Under Attack: Glyphosate, Talc, and Cancer. Am J Public Health. 2019 07; 109(7):976-978.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|